SCHEMBL22005185

SCHEMBL22005185

COc1ccc2c(c1)C1(CC(C)(C)CC(C)(C)C1)c1cc(O)c3cc(OC)ccc3c1-2

nearest known ligand 0.34

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 3/20 0.34
KMT2A Q03164 3/20 0.34
GAA P10253 2/20 0.34
MAPT P10636 5/20 0.33
ALDH1A1 P00352 4/20 0.33
PDK2 Q15119 1/20 0.33
APP P05067 1/20 0.33
SNCA P37840 1/20 0.33
ALK Q9UM73 1/20 0.32
SMN1; SMN2 Q16637 2/20 0.32
NPC1 O15118 2/20 0.32
NOTUM Q6P988 1/20 0.32
CA1 P00915 1/20 0.31
CA2 P00918 1/20 0.31
CA4 P22748 1/20 0.31
CA7 P43166 1/20 0.31
CA9 Q16790 1/20 0.31
CNR2 P34972 1/20 0.31
ESR2 Q92731 1/20 0.31
KDM4E B2RXH2 3/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL26452512 0.93 MAPT (0.33) MEN1KMT2AGAAMAPTALDH1A1
SCHEMBL16360204 0.91 MEN1 (0.38) MEN1KMT2AGAAMAPTALDH1A1
SCHEMBL24799510 0.88 MEN1 (0.37) MEN1KMT2AGAAMAPTALDH1A1
SCHEMBL13868706 0.87 ALDH1A1 (0.34) MEN1KMT2AGAAMAPTALDH1A1
SCHEMBL12424698 0.86 PDK2 (0.38) MEN1KMT2AGAAPDK2
SCHEMBL25954584 0.84 MEN1 (0.38) MEN1KMT2AGAAMAPTALDH1A1
SCHEMBL12509870 0.82 PDK2 (0.33) MEN1KMT2AGAAPDK2
SCHEMBL1010429 0.82 ALK (0.40) MEN1KMT2AGAAMAPTALDH1A1
SCHEMBL24604943 0.81 PDK2 (0.32) PDK2
SCHEMBL24605423 0.81 MEN1 (0.32) MEN1KMT2AGAAMAPTALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230242808-A1 PHOTOCHROMIC COMPOUND AND CURABLE COMPOSITION CONTAINING THE PHOTOCHROMIC COMPOUND TOKUYAMA CORPORATION (JP) 2023-08-03 US disclosed
US-20230242808-A1 PHOTOCHROMIC COMPOUND AND CURABLE COMPOSITION CONTAINING THE PHOTOCHROMIC COMPOUND TOKUYAMA CORPORATION (JP) 2023-08-03 US disclosed
US-20230133211-A1 PHOTOCHROMIC CYCLIC COMPOUND AND CURABLE COMPOSITION CONTAINING THE PHOTOCHROMIC CYCLIC COMPOUND TOKUYAMA CORPORATION (JP) 2023-05-04 US disclosed
EP-3653615-B1 CHROMENE COMPOUND, CURABLE COMPOSITION COMPRISING SAME, AND OPTICAL ARTICLE COMPRISING CURED PRODUCT FORMED OF CURABLE COMPOSITION TOKUYAMA CORP (JP) 2023-03-01 EP disclosed
US-20200190106-A1 CHROMENE COMPOUND, CURABLE COMPOSITION COMPRISING THE COMPOUND, AND OPTICAL ARTICLE INCLUDING A CURED BODY OF THE CURABLE COMPOSITION TOKUYAMA CORPORATION (JP) 2020-06-18 US disclosed
EP-3653615-A1 CHROMENE COMPOUND, CURABLE COMPOSITION COMPRISING SAME, AND OPTICAL ARTICLE COMPRISING CURED PRODUCT FORMED OF CURABLE COMPOSITION Tokuyama Corporation (JP) 2020-05-20 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20200190106-A1 CHROMENE COMPOUND, CURABLE COMPOSITION COMPRISING THE COMPOUND, AND OPTICAL ARTICLE INCLUDING A CURED BODY OF THE CURABLE COMPOSITION INCENP, SMCHD1, ILK MEN1 775/4885KMT2A 2871/4885GAA 4499/4885
US-20230242808-A1 PHOTOCHROMIC COMPOUND AND CURABLE COMPOSITION CONTAINING THE PHOTOCHROMIC COMPOUND RB1, CRY2, CDK16 MEN1 2676/4885KMT2A 579/4885GAA 4429/4885
US-20230133211-A1 PHOTOCHROMIC CYCLIC COMPOUND AND CURABLE COMPOSITION CONTAINING THE PHOTOCHROMIC CYCLIC COMPOUND CRY1, CCNL2, CCNT1 MEN1 847/4885KMT2A 2619/4885GAA 4026/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.